Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CEL | P19835 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13502111 | 0.78 | GPR35 (0.33) | GPR35 | |
| SCHEMBL3561513 | 0.73 | GPR35 (0.36) | GPR35PSMB5 | |
| SCHEMBL3561516 | 0.73 | GPR35 (0.36) | GPR35PSMB5 | |
| SCHEMBL3557120 | 0.73 | GPR35 (0.36) | GPR35PSMB5 | |
| SCHEMBL18825990 | 0.71 | CEL (0.35) | ALDH1A1CELPTGDR2 | |
| SCHEMBL8167373 | 0.69 | LMNA (0.36) | ALDH1A1CEL | |
| SCHEMBL2064365 | 0.66 | — | — | |
| SCHEMBL13502112 | 0.66 | GPR35 (0.30) | GPR35 | |
| SCHEMBL15173081 | 0.66 | PSMB5 (0.45) | PSMB5ALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL28798974 | 0.66 | HTR2C (0.41) | PSMB5ALDH1A1CELPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7663301-B2 | for use as robust red organic phosphors | GENERAL ELECTRIC COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-7663301-B2 | for use as robust red organic phosphors | GENERAL ELECTRIC COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-7663301-B2 | for use as robust red organic phosphors | GENERAL ELECTRIC COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2006076247-A2 | PHOSPHORESCENT FLUORENE, ANTHRACENE AND/OR THIOPHENE SUBSTITUTED METALLO- PORPHYRINS AND RELATED COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060152149-A1 | Porphyrin compositions | GENERAL ELECTRIC COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060152149-A1 | Porphyrin compositions | ACP1, MMS19, MVD | GPR35 3198/4885PSMB5 3272/4885ALDH1A1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.